Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease
March 3, 2021 | Dana Rodriguez
At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.